English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  51934111    線上人數 :  939
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"tai w t"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 26-35 / 66 (共7頁)
<< < 1 2 3 4 5 6 7 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2021-07-03T03:34:35Z Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma Tai W.-T.; Cheng A.-L.; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN; Chen K.-F.
臺大學術典藏 2021-07-03T03:34:30Z Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity Chen K.-F.; Tai W.-T.; Hsu C.-Y.; Huang J.-W.; Liu C.-Y.; PEI-JER CHEN; Kim I.; Shiau C.-W.
臺大學術典藏 2021-07-03T03:34:29Z Synthesis and biological activity of obatoclax derivatives as novel and potent SHP-1 agonists Su J.-C.; Chen K.-F.; Chen W.-L.; Liu C.-Y.; Huang J.-W.; Tai W.-T.; PEI-JER CHEN; Kim I.; Shiau C.-W.
臺大學術典藏 2021-07-03T03:34:27Z Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3 Tai W.-T.; Cheng A.-L.; Shiau C.-W.; Liu C.-Y.; Ko C.-H.; Lin M.-W.; PEI-JER CHEN; Chen K.-F.
臺大學術典藏 2021-07-03T03:34:26Z Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3 Chen K.-F.; Chen H.-L.; Liu C.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN; Cheng A.-L.
臺大學術典藏 2021-07-03T03:34:25Z Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells Chen K.-F.; Lin J.-P.; Shiau C.-W.; Tai W.-T.; Liu C.-Y.; Yu H.-C.; PEI-JER CHEN; Cheng A.-L.
臺大學術典藏 2021-07-03T03:34:23Z Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells Tai W.-T.; Shiau C.-W.; Chen H.-L.; Liu C.-Y.; Lin C.-S.; Cheng A.-L.; PEI-JER CHEN; Chen K.-F.
臺大學術典藏 2021-07-03T03:34:22Z Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody Chen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN; Cheng A.-L.
臺大學術典藏 2021-07-03T03:34:13Z SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model Tai W.-T.; Shiau C.-W.; Li Y.-S.; Chen Y.-L.; Chu P.-Y.; Huang J.-W.; Hsu C.-Y.; Hsu Y.-C.; PEI-JER CHEN; Chen K.-F.
臺大學術典藏 2021-07-03T03:34:12Z Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma Tai W.-T.; Shiau C.-W.; PEI-JER CHEN; Chu P.-Y.; Huang H.-P.; Liu C.-Y.; Huang J.-W.; Chen K.-F.

顯示項目 26-35 / 66 (共7頁)
<< < 1 2 3 4 5 6 7 > >>
每頁顯示[10|25|50]項目